TY - JOUR 
A1 - Marty, F. M.
AU - Man, C. Y.
AU - Van der Horst, C.
AU - Francois, B.
AU - Garot, D.
AU - Mánez, R.
AU - Thamlikitkul, V.
AU - Lorente Balanza, José Ángel
AU - Álvarez Lerma, Francisco
AU - Brealey, D.
AU - Zhao, H. H.
AU - Weller, S.
AU - Yates, P. J.
AU - Peppercorn, A. F.
T1 - Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study
Y1 - 2014
SN - 00221899

UR - http://hdl.handle.net/11268/4210
AB - Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days. Primary outcomes included adverse events (AEs), and clinical/laboratory parameters. Pharmacokinetics, viral load, and disease course were also assessed.
KW - Zanamivir
KW - Medicamentos
KW - Investigación médica
LA - spa
ER -